Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$71.21 USD

71.21
1,484,211

-0.73 (-1.02%)

Updated Oct 2, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

SmileDirectClub (SDC) Introduces Two New Water Flossers

SmileDirectClub (SDC) launched the new Large Tank and Compact Water Flossers, currently available at Shop.SmileDirectClub.com, Amazon, Walmart and Walmart.com.

Breast Health Sales to Drive Hologic's (HOLX) Q4 Earnings

The acquisition of Biotheranostics and the launch of new software are expected to have contributed to Hologic's (HOLX) Breast Health arm performance in the fourth quarter.

Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

Hologic's (HOLX) recent acquisitions and product launches are expected to contribute significantly to its fourth-quarter performance.

Here's Why You Should Hold on to Walgreens Boots (WBA) for Now

Investors are optimistic about Walgreens Boots (WBA) given its better-than-expected fourth-quarter fiscal 2021 results and strategic alliances.

QIAGEN's (QGEN) New Manchester Facility to Fortify UK Foothold

QIAGEN's (QGEN) new campus is expected to bring the benefits of transformational molecular diagnostics to Manchester and the global healthcare market.

Bio-Rad (BIO) to Report Q3 Earnings: What's in the Cards?

Recovery in Clinical Diagnostics arm and strong growth in Droplet Digital PCR platform are expected to have contributed to Bio-Rad's (BIO) Q3 results.

Align Technology (ALGN) to Post Q3 Earnings: What's in Store?

Continued strong adoption of Invisalign Clear Aligners and iTero scanners is expected to contribute to Align Technology's (ALGN) third-quarter 2021 results.

Insulet's (PODD) Omnipod Sales Grow on New Product Upgrade

Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.

Here's Why You Should Retain Bio-Rad (BIO) Stock For Now

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

QIAGEN (QGEN) New Launch to Aid Global TB Elimination Targets

QIAGEN's (QGEN) QIAreach QuantiFERON-TB test is now accessible in high burden, low-resource regions.

ResMed (RMD) to Report Q1 Earnings: What's in the Cards?

Strong customer demand and new product launches are likely to contribute to growth in the fiscal first quarter for ResMed (RMD).

Intuitive Surgical's (ISRG) Ion System Backed by Clinical Study

Latest study results of Intuitive Surgical's (ISRG) Ion system indicate the potential for this technology to help safely biopsy small lung nodules.

Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance

According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.

Here's Why You Should Retain Allscripts (MDRX) Stock For Now

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances and various innovation milestones.

LHC Group (LHCG) Reports Impressive Preliminary Q3 Revenues

Growth in LHC Group's (LHCG) revenues in the third quarter is likely to have been boosted by continued strength in its home health and hospice services.

PerkinElmer's (PKI) New Deal to Improve Single-Cell Profiling

PerkinElmer (PKI) partners with Honeycomb Biotechnologies to launch HIVE scRNAseq Solution, which can advance single-cell profiling.

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Here's Why You Should Invest In Henry Schein (HSIC) Now

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.

HSIC or CNMD: Which Is the Better Value Stock Right Now?

HSIC vs. CNMD: Which Stock Is the Better Value Option?

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Cardinal Health's (CAH) Unit Ties Up to Boost Diabetes Care

Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments.

Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care

Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.